Post-marketing surveillance of the safety of levofloxacin in Japan

Chemotherapy

Volumn 53, Issue 2, 2007, Pages 85-103

  Yamaguchi, Hiroki ^a   Kawai, Hitomi ^a   Matsumoto, Takuyuki ^a   Yokoyama, Hiroo ^a   Nakayasu, Toshio ^a   Komiya, Masahiro ^a   Shimada, Jingoro ^b  

^a DAIICHI SANKYO CO   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse reactions; Central nervous system; Convulsions; Levofloxacin; Post marketing surveillance; Quinolone

Indexed keywords

CAFFEINE; DICLOFENAC; LEVOFLOXACIN; LOXOPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; PARACETAMOL; PHENYLACETIC ACID; PROPIONIC ACID; SALICYLAMIDE; STEROID;

ACHILLES TENDON DISORDER; ADOLESCENT; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BILIARY TRACT DISEASE; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BLOOD DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COMORBIDITY; CONVULSION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DIZZINESS; DRUG SAFETY; ERYTHROCYTE DISORDER; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GENERAL DISORDER; HEADACHE; HEARING DISORDER; HEART ARRHYTHMIA; HEPATOBILIARY DISEASE; HUMAN; HYPERGLYCEMIA; HYPOACUSIS; HYPOGLYCEMIA; IMMUNOPATHOLOGY; INCIDENCE; INTESTINE INFECTION; JAPAN; KIDNEY DISEASE; LEUKOCYTE DISORDER; LIVER DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL SYSTEM MALFORMATION; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATORY TRACT INFECTION; RETICULOENDOTHELIUM SYSTEM DISORDER; RISK FACTOR; SKIN DISEASE; STATISTICAL SIGNIFICANCE; SUBCUTANEOUS TISSUE DISORDER; TENDINITIS; THROMBOCYTE ANOMALY; TORSADE DES POINTES; URINARY TRACT DISEASE; URINARY TRACT INFECTION; VESTIBULAR DISORDER; VISUAL DISORDER;

ACHILLES TENDON; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; HYPOGLYCEMIA; JAPAN; LIVER DISEASES; LONG QT SYNDROME; MALE; MIDDLE AGED; OFLOXACIN; PHOTOSENSITIVITY DISORDERS; PRODUCT SURVEILLANCE, POSTMARKETING; SEIZURES; TORSADES DE POINTES;

EID: 33847742579     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099032     Document Type: Article

References (28)

1. Pharmaceutical Affairs Bureau of the Ministry of Health and Welfare: Information on Adverse Drug Reactions No. 81, 1986.
2. Pharmaceutical Affairs Bureau of the Ministry of Health and Welfare: Information on Adverse Drug Reactions No. 127, 1994.
3. Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH: Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002;113:232-234.
4. Chen HJL, Bloch KJ, Maclean JA: Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med 2000;342:359-360.
5. Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B: Torsades de pointe probably related to sparfloxacin. Eur J Clin Microbiol Infect Dis 1996;15:350-351.
6. Hayakawa I, Atarashi S, Yokohama S, Imamura M, Sakano K, Furukawa M: Synthesis and antibacterial activity of an optical isomer of OFX. Antimicrob Agents Chemother 1986;29:163-164.
7. Une T, Fujimoto T, Sato K, Osada Y: In vitro activity of DR-3355, an active optical isomer of ofloxacin. Antimicrob Agents Chemother 1988;32:1336-1340.
8. Fujimoto T, Mitsuhashi S: In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin. Chemotherapy 1990;36:268-276.
9. Tanaka M, Otsuki M, Une T, Nishino T: In vitro and in vivo activity of DR-3355, an active optical isomer of ofloxacin. Antimicrob Agents Chemother 1990;26:659-666.
10. Soejima R, Kawane H, Okimoto J, et al: Double-blind comparison study between LVX and ofloxacin in patients with bacterial pneumonia. Chemotherapy 1992;40:121-146.
11. Soejima R, Kawane H, Okimoto J, et al: Double-blind comparison study between LVX and ofloxacin in patients with chronic lower airway infections. Chemotherapy 1992;40:97-120.
12. Kawada Y, Moridono S, Kumamoto E, et al: Double-blind comparison study between levo-floxacin and ofloxacin in patients with complicated urinary tract infections. Chemotherapy 1992;40:230-248.
13. Hori S, Shimada J, Saito J, Matsda M, Miyahara T: Comparison of the inhibitory effects of new quinolones on γ-aminobutyric acid receptor binding in the presence of antiinflammatory drugs. Rev Infect Dis 1989;11:S1397-S1398.
14. Hori S: New quinolone agents and nonsteroidal anti-inflammatory agents. Infect Antibact Age 2000;3:191-196.
15. Sawada Y: Convulsions due to new quinolone antibacterial agents. Pharm Mon 1998;40:923-933.
16. Nozaki M: Convulsions due to coadministration of new quinolone agents and nonsteroidal anti-inflammatory agents. J Ther 1994;76:2265-2271.
17. Hori S: A study on the mechanism of onset of convulsions due to interactions between quinolones and anti-inflammatory agents: classification and correlation of structure-activity relationships of anti-inflammatory agents investigated from the standpoint of drug interactions. Jpn J Antibiot 2000;53:249-252.
18. Hori S, Kawamura M: Drug interactions with quinolone agents from the standpoint of nonsteroidal anti-inflammatory agents: comparison between gatifloxacin and norfloxacin. Chemotherapy 2002;50:460-463.
19. Hori S, Kizu J, Kawamura M: Effects of antiinflammatory drugs on convulsant activity of quinolones: a comparative study of drug interaction between quinolones and anti-inflammatory drugs. J Infect Chemother 2003;9:314-320.
20. Kato M, Furuhama K, Yoshida M, Akahane K, Takayama S: Acute oral toxicity of the new quinolone antibacterial agent levofloxacin in mice, rats, and monkeys. Drug Res 1992;42:365-366.
21. Kato M, West HA, Ashby R, Virgo DM, Fowler JS, Furuhama K, Takayama S: Four-week sub-acute toxicity study of S-(-)-9-fluoro-2,3-dihydro-3-methyl-10-(4- methyl-1-piperazinyl)-7-oxo-7H-pyrido-[1,2,3,-de][1,4]benzoxazine-6-carboxylic acid hemihydrate (DR-3355) in CD rats and cynomolgus monkeys. J Toxicol Sci 1991;16:29-48.
22. Kato M, Furuhama K, Woolley AP, Ashby R, Fowler JS, Takayama S: Twenty-six-week oral toxicity of the new quinolone antibacterial agent levofloxacin in rats and cynomolgus monkeys. Drug Res 1992;42:367-373.
23. Ponti FD, Poluzzi E, Montanaro N: QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000;56:1-18.
24. + channel HERG. Mol Pharmacol 2001;59:122-126.
25. Hagiwara T, Satoh S, Kasai Y, Takasuna K: A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardium. Jpn J Pharmacol 2001;87:231-234.
26. Rothschild E, Saint-Pierre A: Tavanic-important pharmacovigilance information concerning Tavanic (levofloxacin). Paris, Department of Health, December 17, 2001.
27. Domagala JM: Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994;33:685-706.
28. Bowie WR, Willetts V, Jewesson PJ: Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrob Agents Chemother 1989;33:1778-1782.